|Mr. Bruno Grange||International Controller & Director||131.38k||N/A||1953|
|Ms. Valérie Poinsot||Director of Devel., Deputy GM & Exec. Director||1.02M||N/A||1969|
|Mr. Jean-Christophe Bayssat||Chief Pharmacist, Director of Pharmaceutical Devel. & Deputy GM||981.46k||N/A||1963|
|Mr. Christian Boiron||GM & Exec. Director||865.52k||N/A||1948|
|Fabrice Rey||Group Treasurer||N/A||N/A||N/A|
Boiron SA, through its subsidiaries, engages in the manufacture and sale of homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines; and proprietary, branded homeopathic medicines. Its branded homeopathic medicines are used for the treatment of influenza symptoms; coughs; benign trauma in the absence of open wounds; bruising, contusions, and muscle fatigue; teething problems for nursing babies; anxiety and emotional disorders, and minor sleep disorders; cold symptoms and rhinitis; ocular discomfort and irritation due to various causes for adults and children; and vocal disorders. The company offers its products through distribution centers, pharmacy chains, wholesalers, supermarkets, drugstores, and health food stores. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Boiron SA’s ISS governance QualityScore as of 1 May 2018 is 10. The pillar scores are Audit: 1; Board: 9; Shareholder rights: 7; Compensation: 9.